GleamWall
中文EN

CLNN Clene Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1822791 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-47.7%
TTM net income YoY20.4%
TTM EPS YoY—
Revenue 3-yr CAGR-22.1%
Net income 3-yr CAGR—

Margins

Gross margin79.5%
Operating margin-9,676.3%
Net margin-11,520.5%
FCF margin-6,240.1%
EBITDA margin-9,195.3%

Returns

ROE-1,738.4%
ROA-98.9%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets132.4%
Debt / equity—
Current ratio1.57x
Interest coverage-8.14x

Cash quality & payout

Operating cash flow / net income0.54x
Accruals ratio-45.4%
Payout ratio—
Capex / revenue4.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$200,000$342,000
Cost of revenue$43,000$70,000
Gross profit$157,000$272,000
R&D expense$14.01M$20.06M
SG&A expense$9.23M$13.31M
Operating income-$23.08M-$33.09M
Interest expense$2.68M$4.06M
Pretax income-$26.17M-$39.40M
Income tax$0$0
Net income-$26.17M-$39.40M
EBITDA-$21.59M-$31.45M
EPS (basic)-2.65-5.67
EPS (diluted)——
Balance sheet
Cash & equivalents$5.19M$12.15M
Short-term investments—$0
Receivables$0$64,000
Inventory$37,000$68,000
Current assets$8.98M$16.16M
PP&E, net$6.02M$7.48M
Total assets$18.13M$27.34M
Current liabilities$10.78M$10.29M
Long-term debt$17.79M—
Total debt$17.79M—
Total liabilities$35.72M$36.19M
Shareholders' equity-$17.59M-$8.86M
Net debt$12.60M—
Shares outstanding10.85M8.09M
Cash flow statement
Operating cash flow-$18.55M-$21.33M
Capital expenditure$39,000$15,000
Free cash flow-$18.59M-$21.34M
Investing cash flow-$39,000$6.32M
Financing cash flow$11.52M-$1.53M
Depreciation & amortization$1.50M$1.65M
Stock-based compensation$6.38M$7.95M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.